

Supplementary Table. 1.

The latest medication type among current LLT patients overall and by hierarchical disease categories.

Medication type(%)	Total cohort	ASCVD n=9388				DM alone
	N=10674	Recent ACS n=273	Chronic CHD n=6438	Stroke n=2612	PAD n=65	n=1286
Atorvastatin	40.0	67.0	39.4	40.9	43.1	35.3
Rosuvastatin	31.6	23.4	33.5	27.3	23.1	33.2
Fluvastatin	14.5	4.0	13.6	20.3	6.2	10.4
Pravastatin	7.4	3.3	7.3	6.3	20.0	11.0
Simvastatin	3.9	1.8	4.0	3.3	4.6	5.1
Others	1.4	0.4	1.2	1.7	0.0	1.8


Fibrates	0.9	0.0	0.9	0.3	3.1	2.8
Niacin	0.1	0.0	0.0	0.0	0.0	0.4
Lovastatin	0.0 ^a	0.0	0.0	0.0	0.0	0.0
Cholesterol absorption inhibitors	0.0	0.0	0.0	0.0	0.0	0.0

LLT, lipid-lowering treatment; ASCVD, atherosclerotic cardiovascular disease; ACS, acute coronary syndrome; CHD, coronary heart disease;

DM, diabetes mellitus; PAD, peripheral arterial disease.

a. 0.0% mean no drug utilization or too little utilization.

Supplementary Fig. 1. Patient selection



ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol.